Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Receivables (2021 - 2025)

LifeStance Health (LFST) has disclosed Receivables for 5 consecutive years, with $99.5 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 24.64% to $99.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $99.5 million through Dec 2025, down 24.64% year-over-year, with the annual reading at $99.5 million for FY2025, 24.64% down from the prior year.
  • Receivables for Q4 2025 was $99.5 million at LifeStance Health, down from $121.1 million in the prior quarter.
  • The five-year high for Receivables was $175.9 million in Q1 2024, with the low at $64.6 million in Q2 2021.
  • Average Receivables over 5 years is $120.2 million, with a median of $121.1 million recorded in 2025.
  • The sharpest move saw Receivables surged 54.47% in 2022, then fell 24.64% in 2025.
  • Over 5 years, Receivables stood at $95.3 million in 2021, then increased by 6.46% to $101.5 million in 2022, then grew by 23.77% to $125.6 million in 2023, then increased by 5.08% to $132.0 million in 2024, then dropped by 24.64% to $99.5 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $99.5 million, $121.1 million, and $129.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.